Artificial intelligence and network pharmacology based investigation of pharmacological mechanism and substance basis of Xiaokewan in treating diabetes.
Animals
Animals, Genetically Modified
Artificial Intelligence
Biomarkers
/ blood
Blood Glucose
/ drug effects
Chromatography, High Pressure Liquid
Data Mining
Diabetes Mellitus
/ blood
Disease Models, Animal
Drugs, Chinese Herbal
/ pharmacology
Gene Regulatory Networks
Hypoglycemic Agents
/ pharmacology
Male
Protein Interaction Maps
Rats, Wistar
Spectrometry, Mass, Electrospray Ionization
Systems Biology
Tandem Mass Spectrometry
Workflow
Zebrafish
/ embryology
Background exclusion data dependent acquisition
Chinese traditional medicine
Diabetes
Metabolites
Network pharmacology
Non-targeted data mining
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
19
03
2020
revised:
14
05
2020
accepted:
14
05
2020
pubmed:
29
5
2020
medline:
7
7
2021
entrez:
29
5
2020
Statut:
ppublish
Résumé
Xiaokewan is a typical Traditional Chinese medicine (TCM) for diabetes and contains various natural chemicals, such as lignans, flavonoids, saponins, polysaccharides, and western medicine glibenclamide. In the current study, a highly efficient system for screening hypoglycemic efficacy constituents of Xiaokewan has been developed with the integration of intelligent data acquisition, data mining, network pharmacology, and computer assisted target fishing. With the combination of background exclusion data dependent acquisition (BE-DDA) and non-targeted precise-and-thorough background-subtraction (PATBS) techniques, a novel workflow has been established for the non-targeted recognition and identification of TCM constituents in vivo, and has been applied to the exposure study of Xiaokewan in rat. In this case, an interesting correlation among drug, target, and disease can be established, by combining the screening or characterization results with the strategy of network pharmacology and multiple computer assisted techniques. Consequently, five main constituents (puerarin, daidzein, formononetin, deoxyschizandrin and glibenclamide) exposed in vivo have been selected as effective hypoglycemic components. Meanwhile, the network pharmacology experimental results showed that these five constituents could act on various drug targets, such as PI3K, PTP1B, MAPK, AKT, TNF, and NF-κB. These five constituents might be involved in the regulation of β-cell function or exhibit inflammation inhibition ability to relieve the pathophysiological process of disease from multiple links. Furthermore, the pharmacological effects of these five constituents have been verified by diabetic zebrafish model. The zebrafish model results showed that the TCM monomer mixture without glibenclamide exhibited similar hypoglycemic activity with Xiaokewan. Although the monomer mixture with glibenclamide showed better activity than Xiaokewan only, the deoxyschizandrin (TCM constituent of Xiaokewan) exhibited best hypoglycemic performance. In summary, the above results indicated that the application of both intelligent recognition technology in mass spectrometry dataset and computerized network pharmacology might provide a pioneering approach for investigating the substance basis of TCM and searching lead compounds from natural sources.
Identifiants
pubmed: 32464328
pii: S1043-6618(20)31243-3
doi: 10.1016/j.phrs.2020.104935
pii:
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Drugs, Chinese Herbal
0
Hypoglycemic Agents
0
xiaokewan
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104935Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.